287 related articles for article (PubMed ID: 12406913)
1. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
[TBL] [Abstract][Full Text] [Related]
2. B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.
Hodawadekar S; Yu D; Cozma D; Freedman B; Sunyer O; Atchison ML; Thomas-Tikhonenko A
Exp Cell Res; 2007 Jan; 313(2):331-40. PubMed ID: 17098231
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
4. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
5. Multiple hematopoietic cell lineages develop in vivo from transplanted Pax5-deficient pre-B I-cell clones.
Schaniel C; Bruno L; Melchers F; Rolink AG
Blood; 2002 Jan; 99(2):472-8. PubMed ID: 11781227
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Notch1 function by in vitro T cell differentiation of Pax5 mutant lymphoid progenitors.
Höflinger S; Kesavan K; Fuxa M; Hutter C; Heavey B; Radtke F; Busslinger M
J Immunol; 2004 Sep; 173(6):3935-44. PubMed ID: 15356142
[TBL] [Abstract][Full Text] [Related]
7. Fidelity and infidelity in commitment to B-lymphocyte lineage development.
Rolink AG; Schaniel C; Busslinger M; Nutt SL; Melchers F
Immunol Rev; 2000 Jun; 175():104-11. PubMed ID: 10933595
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5.
Pongubala JM; Northrup DL; Lancki DW; Medina KL; Treiber T; Bertolino E; Thomas M; Grosschedl R; Allman D; Singh H
Nat Immunol; 2008 Feb; 9(2):203-15. PubMed ID: 18176567
[TBL] [Abstract][Full Text] [Related]
9. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
10. Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis.
Nutt SL; Eberhard D; Horcher M; Rolink AG; Busslinger M
Int Rev Immunol; 2001 Feb; 20(1):65-82. PubMed ID: 11342298
[TBL] [Abstract][Full Text] [Related]
11. Reversion of B cell commitment upon loss of Pax5 expression.
Mikkola I; Heavey B; Horcher M; Busslinger M
Science; 2002 Jul; 297(5578):110-3. PubMed ID: 12098702
[TBL] [Abstract][Full Text] [Related]
12. Myeloid lineage switch of Pax5 mutant but not wild-type B cell progenitors by C/EBPalpha and GATA factors.
Heavey B; Charalambous C; Cobaleda C; Busslinger M
EMBO J; 2003 Aug; 22(15):3887-97. PubMed ID: 12881423
[TBL] [Abstract][Full Text] [Related]
13. Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development.
Simmons S; Knoll M; Drewell C; Wolf I; Mollenkopf HJ; Bouquet C; Melchers F
Blood; 2012 Nov; 120(18):3688-98. PubMed ID: 22927250
[TBL] [Abstract][Full Text] [Related]
14. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic effect of CCAAT enhancer-binding protein-alpha and Pax5 in myeloid or lymphoid lineage choice in common lymphoid progenitors.
Hsu CL; King-Fleischman AG; Lai AY; Matsumoto Y; Weissman IL; Kondo M
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):672-7. PubMed ID: 16407117
[TBL] [Abstract][Full Text] [Related]
16. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
[TBL] [Abstract][Full Text] [Related]
17. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
18. Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B-cell leukemia.
Hentges KE; Weiser KC; Schountz T; Woodward LS; Morse HC; Justice MJ
Oncogene; 2005 Feb; 24(7):1220-30. PubMed ID: 15580294
[TBL] [Abstract][Full Text] [Related]
19. Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors.
Rolink AG; Nutt SL; Melchers F; Busslinger M
Nature; 1999 Oct; 401(6753):603-6. PubMed ID: 10524629
[TBL] [Abstract][Full Text] [Related]
20. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny.
Dworzak MN; Fritsch G; Fröschl G; Printz D; Gadner H
Blood; 1998 Nov; 92(9):3203-9. PubMed ID: 9787156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
